RT Journal Article
SR Electronic
T1 Omicron (BA.1) SARS-CoV-2 variant is associated with reduced risk of hospitalization and length of stay compared with Delta (B.1.617.2)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.20.22269406
DO 10.1101/2022.01.20.22269406
A1 Peralta-Santos, André
A1 Rodrigues, Eduardo Freire
A1 Moreno, Joana
A1 Ricoca, Vasco
A1 Casaca, Pedro
A1 Fernandes, Eugenia
A1 Gomes, João Paulo
A1 Ferreira, Rita
A1 Isidro, Joana
A1 Pinto, Miguel
A1 Borges, Vítor
A1 Vieira, Luís
A1 Duarte, Sílvia
A1 Sousa, Carlos
A1 Almeida, José Pedro
A1 Menezes, Luís
A1 Ferreira, Bibiana I.
A1 Matias, Ana
A1 Pelerito, Ana
A1 Freire, Samanta
A1 Grilo, Teresa
A1 Borges, Cláudia Medeiros
A1 Moutinho, Vera
A1 Leite, Andreia
A1 Kislaya, Irina
A1 Rodrigues, Ana Paula
A1 Leite, Pedro Pinto
A1 Nunes, Baltazar
YR 2022
UL http://medrxiv.org/content/early/2022/01/25/2022.01.20.22269406.abstract
AB Introduction Early reports showed that Omicron (BA.1) SARS-CoV-2 could be less severe. However, the magnitude of risk reduction of hospitalization and mortality of Omicron (BA.1) infections compared with Delta (B.1.617.2) is not yet clear. This study compares the risk of severe disease among patients infected with the Omicron (BA.1) variant with patients infected with Delta (B.1.617.2) variant in Portugal.Methods We conducted a cohort study in individuals diagnosed with SARS-CoV-2 infection between 1st and 29th December 2021. Cases were individuals with a positive PCR test notified to the national surveillance system. SARS-CoV-2 variants were classified first by whole genomic sequencing (WGS) and, if this information was unavailable, by detecting the S gene target failure. We considered a hospitalization for all the patients admitted within the 14 days after the SARS-CoV-2 infection; after that period, they were censored.The comparison of the risk of hospitalization between Omicron (BA.1) and Delta (B.1.617.2) VOC was estimated using a Cox proportional hazards model. The mean length of stay was compared using linear regression, and the risk of death between Omicron and Delta patients was estimated with a penalized logistic regression. All models were adjusted for sex, age, previous infection, and vaccination status.Results We included 15 978 participants aged 16 or more years old, 9 397 infected by Delta (B.1.617.2) and 6 581 infected with Omicron (BA.1). Within the Delta (B.1.617.2) group, 148 (1.6%) were hospitalized, and 16 (0.2%) were with the Omicron (BA.1). A total of 26 deaths were reported, all in participants with Delta (B.1.617.2) infection. Adjusted HR for hospitalization for the Omicron (BA.1) variant compared with Delta (B.1.617.2) was 0.25 (95%CI 0.15 to 0.43). The length of stay in hospital for Omicron (BA.1) patients was significantly shorter than for Delta (confounding-adjusted difference -4.0 days (95%CI -7.2 to -0.8). The odds of death were 0.14 (95% CI 0.0011 to 1.12), representing a reduction in the risk of death of 86% when infected with Omicron (BA.1) compared with Delta (B.1.617.2).Conclusion Omicron (BA.1) was associated with a 75% risk reduction of hospitalization compared with Delta (B.1.617.2) and reduced length of hospital stay.Competing Interest StatementAPS - Has stocks of pharmaceutical companies and is in an advisory board of a COVID-19 drugFunding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Portuguese National Institute of Health gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors